• What are the Different Types of Liver Cancer, and How do They Develop?

What are the Different Types of Liver Cancer, and How do They Develop?

A review article in the March issue of Gastroenterology discusses different hypotheses about the cells responsible for liver tumorigenesis. The article also reviews the different classes of liver tumors, based on the molecular features, and how these affect patient prognosis. Daniela Sia et al describe the distinct molecular and clinical features of hepatocellular

Read more
  • How Can We Study Genetic Heterogeneity Within Hepatocellular Carcinomas?

How Can We Study Genetic Heterogeneity Within Hepatocellular Carcinomas?

Researchers have developed a patient-derived cell line-based model to study how intratumor heterogeneity affects sensitivity of hepatocellular carcinoma (HCC) to different therapeutic agents, reported in the January issue of Gastroenterology. HCCs have a large amount of genetic heterogeneity within each tumor, making them difficult to treat. Multiple regions of tumors

Read more
  • A Forward Genetic Screen Identifies Suppressors of Hepatocellular Carcinogenesis

A Forward Genetic Screen Identifies Suppressors of Hepatocellular Carcinogenesis

Using 2 powerful high-throughput in vivo screening tools, researchers identified and validated 27 genes as suppressors of hepatocellular carcinoma (HCC), reported in the August issue of Gastroenterology. Their findings support the role of Ras signaling in development of HCC and provide new therapeutic targets. Sorafenib is the only treatment for patients

Read more
  • Does a PNPLA3 Polymorphism Promote Fibrosis Progression in Patients with Hepatitis C?

Does a PNPLA3 Polymorphism Promote Fibrosis Progression in Patients with Hepatitis C?

A single nucleotide polymorphism (SNP) in the patatin-like phospholipase domain containing 3 gene (PNPLA3) is associated with baseline level of fibrosis and its progression, but not development of hepatocellular carcinoma (HCC), in patients with hepatitis C virus (HCV) infection, researchers report in the February issue of Clinical Gastroenterology and Hepatology. Most

Read more

How Can We Tell if Patients are Still at Risk for HCC after HCV Therapy?

For patients with chronic Hepatitis C virus infection, high levels of α-fetoprotein after therapy can identify those at risk for hepatocellular carcinoma (HCC), researchers report in the July issue of Clinical Gastroenterology and Hepatology. In persons with chronic HCV infection, lack of sustained virologic response (SVR) 24 weeks after the end

Read more